公开(公告)号：US11413270B2

公开(公告)日：2022-08-16

申请号：US16908195

申请日：2020-06-22

Applicant: NOVMETAPHARMA CO., LTD.

Inventor： Heon Jong Lee ,  Hoe Yune Jung ,  In-Kyu Lee ,  Jae-Han Jeon ,  Sung Jin Cho

IPC: A61K31/397 ,  A61K31/495 ,  A61K31/4453 ,  A61K31/5375 ,  A61K31/4025 ,  A61P1/18 ,  A61K31/454 ,  A61K31/407 ,  A61K31/4525 ,  A61K31/403 ,  A61K31/4192 ,  A61K31/396

Abstract: A composition for preventing and/or treating pancreatitis and a method of prevention and/or treatment of pancreatitis are disclosed. The composition include an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. The method includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof.

公开(公告)号：US11850246B2

公开(公告)日：2023-12-26

申请号：US17393587

申请日：2021-08-04

Applicant: NOVMETAPHARMA CO., LTD.

Inventor： In-Kyu Lee ,  Jae-Han Jeon ,  Dipanjan Chanda ,  Eun Jung Choi ,  Hoe-Yune Jung ,  Heon Jong Lee

IPC: A61K31/495 ,  A61P29/00

CPC classification number: A61K31/495

Abstract: A composition for preventing and/or treating cytokine release syndrome and a method of prevention and/or treatment of cytokine release syndrome are disclosed. The composition includes an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. The method includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof. The cytokine release syndrome may be caused by virulent infection. The administration of the compound reduces the pre-inflammatory cytokine levels in the subject.

公开(公告)号：US20210401880A1

公开(公告)日：2021-12-30

申请号：US17292238

申请日：2019-11-05

Applicant: Novmetapharma Co., Ltd.

Inventor： Heon Jong Lee ,  Kay Olmstead ,  Moon Ki Song ,  Kyong-Tai Kim ,  In-Kyu Lee ,  Hoe-Yune Jung

IPC: A61K33/30 ,  A61K38/05 ,  A61P3/10 ,  A61P3/04

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating obesity, comprising cyclo-hispro as an active ingredient. Specifically, the present invention has the effect of reducing body weight and body mass, and further improving leptin resistance. In addition, the present invention relates to a pharmaceutical composition for preventing or treating obesity, characterized in that the pharmaceutical composition comprises cyclo-hispro and zinc and is administered once a day.

公开(公告)号：US20210100872A1

公开(公告)日：2021-04-08

申请号：US16956109

申请日：2018-12-11

Applicant: Novmetapharma Co., Ltd.

Inventor： Heon Jong Lee ,  Kay Olmstead ,  Moon Ki Song ,  Kyong-Tai Kim ,  In-Kyu Lee ,  Hoe-Yune Jung

IPC: A61K38/12 ,  A61K33/30 ,  A61P3/10 ,  A61K9/48

Abstract: The present invention relates to a pharmaceutical formulation for preventing or treating diabetes mellitus, comprising cyclo-hispro as an active ingredient. Specifically, the present invention has the effect of lowering the concentration of glycated hemoglobin (HbA1c) in the blood, and further improving leptin resistance. In addition, the present invention relates to a pharmaceutical formulation for preventing or treating diabetes mellitus, characterized in that the pharmaceutical formulation comprises cyclo-hispro and zinc and is administered once a day.

公开(公告)号：US20220362269A1

公开(公告)日：2022-11-17

申请号：US17852774

申请日：2022-06-29

Applicant: NovMetaPharma Co., Ltd.

Inventor： Heon Jong LEE ,  Heo Yune Jung ,  In-Kyu Lee ,  Jae-Han Jeon ,  Sung Jin Cho ,  Jina Kim ,  Hayoung Hwang ,  Yong Hyun Jeon ,  Jungwook Chin

IPC: A61K31/695 ,  A61K31/495 ,  A61K31/4453 ,  A61K31/5375 ,  A61K31/40 ,  A61K31/396 ,  A61K31/397 ,  A61K31/454 ,  A61K31/4025 ,  A61K31/407 ,  A61K31/443 ,  A61K31/403 ,  A61K31/433 ,  A61P1/18

Abstract: A composition for preventing and/or treating pancreatitis and a method of prevention and/or treatment of pancreatitis are disclosed. The composition include an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. Also disclosed is a use of the aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, in manufacturing a medicament for preventing and/or treating pancreatitis or for treating one or more symptoms of pancreatitis in a patient. The method of prevention and/or treatment of pancreatitis includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof.